Effect of commercial ethanol propolis extract on the in vitro growth of Candida albicans collected from HIV-seropositive and HIV-seronegative Brazilian patients with oral candidiasis.
The present study assessed the susceptibility of Candida albicans strains, collected from HIV-positive patients with oral candidiasis, to a commercial 20% ethanol propolis extract (EPE) and compare it to the inhibitory action of the standardized antifungal agents nystatin (NYS), clotrimazole (CL), econazole (EC), and fluconazole (FL). Twelve C. albicans strains collected from HIV-positive patients with oral candidiasis were tested. The inhibition zones were measured with a pachimeter and the results are reported as means and standard deviation (M +/- SD). Data were analyzed statistically by the non-parametric Kruskal-Wallis test. EPE inhibited all the C. albicans strained tested. No significant difference was observed between the results obtained with NYS and EPE, while significant differences were observed between EPE and other antifungals. The C. albicans strains tested showed resistance to the remaining antifungal agents. The propolis extract used in this study inhibited the in vitro growth of C. albicans collected from HIV-seropositive Brazilian patients, creating/forming inhibition zones like those ones formed by NYS. This fact suggests that commercial EPE could be an alternative medicine in the treatment of candidiasis from HIV-positive patients. However, in vivo studies of the effect of EPE are needed to determine its possible effects on the oral mucosa.
Martins
Rachel S
RS
Department of Clinical Pathology and Surgery, School of Dentistry, Minas Gerais Federal University, Belo Horizonte, Brazil.
Péreira
Erika S J
ES
Lima
Sérgio M
SM
Senna
Maria I B
MI
Mesquita
Ricardo A
RA
Santos
Vagner R
VR
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001938:Brazil; D002176:Candida albicans / Q000145:classification / Q000187:drug effects* / Q000254:growth & development; D002180:Candidiasis, Oral / Q000188:drug therapy*; D003022:Clotrimazole / Q000627:therapeutic use; D000529:Complementary Therapies; D025141:Drug Resistance, Fungal; D004464:Econazole / Q000627:therapeutic use; D000431:Ethanol; D015725:Fluconazole / Q000627:therapeutic use; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000382:microbiology*; D006801:Humans; D009761:Nystatin / Q000627:therapeutic use; D011429:Propolis / Q000627:therapeutic use*; D012997:Solvents; D018709:Statistics, Nonparametric
D000890:Anti-Infective Agents; D000935:Antifungal Agents; D012997:Solvents; D009761:Nystatin; D000431:Ethanol; D004464:Econazole; D015725:Fluconazole; D011429:Propolis; D003022:Clotrimazole